Accuray (Accuray) Float Percentage Of Total Shares Outstanding : 98.37% (As of May. 01, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Accuray Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Accuray's float shares is 97.56 Mil. Accuray's total shares outstanding is 99.17 Mil. Accuray's float percentage of total shares outstanding is 98.37%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Accuray's Insider Ownership is 12.20%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Accuray's Institutional Ownership is 36.49%.

Accuray Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Accuray's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	97.56	/	99.17
	=	98.37%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accuray (Accuray) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accuray Inc (NAS:ARAY) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

XEJ:Germany

Address

1240 Deming Way, Madison, WI, USA, 53717

Website

https://www.accuray.com

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.

Executives

Gina Corradetti	officer: VP, Corporate Controller	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Ali Pervaiz	officer: SVP Chief Financial Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Jesse Chew	officer: SVP and General Counsel	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Sandeep Chalke	officer: SVP, Chief Commercial Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Suzanne C Winter	officer: SVP & Chief Commercial Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Patrick Spine	officer: SVP, Chief Admin Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Michael Hoge	officer: Senior VP Global Operations	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Kill	director	VIRTUAL RADIOLOGIC CORPORATION, 5995 OPUS PARKWAY, SUITE 200, MINNETONKA MN 55343
Brandon W Green	officer: Chief Financial Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Franco N Palomba	officer: VP, Chief Accounting Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Byron C Scott	director	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Joshua Levine	officer: President & CEO	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Mika Nishimura	director	471 EL CAMINO REAL, SANTA CLARA CA 95050
Joseph E Whitters	director
Shigeyuki Hamamatsu	officer: VP, Finance and CAO	1875 CHARLESTON ROAD, MOUNTAIN VIEW CA 94043